Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists

European Journal of Medicinal Chemistry
2015.0

Abstract

TGR5 (Gpbar-1, M-Bar) is a class A G-protein coupled bile acid-sensing receptor predominately expressed in brain, liver and gastrointestinal tract, and a promising drug target for the treatment of metabolic disorders. Due to the lack of a crystal structure of TGR5, the development of TGR5 agonists has been guided by ligand-based approaches so far. Three binding mode models of bile acid derivatives have been presented recently. However, they differ from one another in terms of overall orientation or with respect to the location and interactions of the cholane scaffold, or cannot explain all results from mutagenesis experiments. Here, we present an extended binding mode model based on an iterative and integrated computational and biological approach. An alignment of 68 TGR5 agonists based on this binding mode leads to a significant and good structure-based 3D QSAR model, which constitutes the most comprehensive structure-based 3D-QSAR study of TGR5 agonists undertaken so far and suggests that the binding mode model is a close representation of the "true" binding mode. The binding mode model is further substantiated in that effects predicted for eight mutations in the binding site agree with experimental analyses on the impact of these TGR5 variants on receptor activity. In the binding mode, the hydrophobic cholane scaffold of taurolithocholate orients towards the interior of the orthosteric binding site such that rings A and B are in contact with TM5 and TM6, the taurine side chain orients towards the extracellular opening of the binding site and forms a salt bridge with R79(EL1), and the 3-hydroxyl group forms hydrogen bonds with E169(5.44) and Y240(6.51). The binding mode thus differs in important aspects from the ones recently presented. These results are highly relevant for the development of novel, more potent agonists of TGR5 and should be a valuable starting point for the development of TGR5 antagonists, which could show antiproliferative effects in tumor cells.

Knowledge Graph

Similar Paper

Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists
European Journal of Medicinal Chemistry 2015.0
Novel Potent and Selective Bile Acid Derivatives as TGR5 Agonists: Biological Screening, Structure−Activity Relationships, and Molecular Modeling Studies
Journal of Medicinal Chemistry 2008.0
Mapping histamine H<sub>4</sub>receptor–ligand binding modes
MedChemComm 2012.0
Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR)
Bioorganic &amp; Medicinal Chemistry Letters 2003.0
Structure−Activity Relationship Study of Betulinic Acid, A Novel and Selective TGR5 Agonist, and Its Synthetic Derivatives: Potential Impact in Diabetes
Journal of Medicinal Chemistry 2010.0
Homology Modeling of Metabotropic Glutamate Receptors. (mGluRs) Structural Motifs Affecting Binding Modes and Pharmacological Profile of mGluR1 Agonists and Competitive Antagonists
Journal of Medicinal Chemistry 1996.0
Molecular modeling aided design of nicotinic acid receptor GPR109A agonists
Bioorganic &amp; Medicinal Chemistry Letters 2008.0
Evaluation of Molecular Modeling of Agonist Binding in Light of the Crystallographic Structure of an Agonist-Bound A<sub>2A</sub>Adenosine Receptor
Journal of Medicinal Chemistry 2012.0
Characterization of the 5-HT<sub>7</sub>Receptor. Determination of the Pharmacophore for 5-HT<sub>7</sub>Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site
Journal of Medicinal Chemistry 2003.0
Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists
Bioorganic &amp; Medicinal Chemistry Letters 2014.0